# Gubra: The Science of Certainty > Gubra is specialized in high\-end preclinical contract research and peptide\-based drug discovery within metabolic and fibrotic diseases\. Generated by Yoast SEO v28.1, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [About Us](https://www.gubra.dk/about-us/) - [Contact us](https://www.gubra.dk/contact/) - [Privacy policy](https://www.gubra.dk/privacy-policy/) - [CRO Services](https://www.gubra.dk/cro-services/) - [Liver \(MASH\)](https://www.gubra.dk/cro-services/liver/) - [MASH \- Clinically Translatable Models of MASH](https://www.gubra.dk/cro-services/liver/nash/) - [Preclinical Models of Obesity](https://www.gubra.dk/cro-services/obesity/preclinical-research-in-obesity/) - [Obesity](https://www.gubra.dk/cro-services/obesity/) - [CKD / DKD / AKI / PKD: Preclinical Models of Kidney Diseases](https://www.gubra.dk/cro-services/kidney/kidney-disease-models/) - [Kidney](https://www.gubra.dk/cro-services/kidney/) - [CNS](https://www.gubra.dk/cro-services/cns/) - [CNS Landing page](https://www.gubra.dk/cro-services/cns/whole-brain-imaging/) - [3D Imaging](https://www.gubra.dk/cro-services/3d-imaging/) - [Lung \(IPF\)](https://www.gubra.dk/cro-services/lung/) - [Non\-rodent studies](https://www.gubra.dk/cro-services/non-rodent-studies/) - [Diabetes](https://www.gubra.dk/cro-services/diabetes/) - [Histology](https://www.gubra.dk/cro-services/2d-histology/) - [Histolopathology services](https://www.gubra.dk/cro-services/2d-histology/histopathology-services/) - [RNASeq](https://www.gubra.dk/cro-services/rna-sequencing/) - [Discovery, Development \& Partnerships](https://www.gubra.dk/biotech/) - [Drug Discovery \& Development](https://www.gubra.dk/biotech/drug-discovery/) - [streaMLine](https://www.gubra.dk/biotech/streamline/) - [R\&D Pipeline](https://www.gubra.dk/biotech/rnd-pipeline/) - [Partnering](https://www.gubra.dk/biotech/partnering/) - [Study Execution Process](https://www.gubra.dk/cro-services/study-execution-process/) - [Blog](https://www.gubra.dk/blog/) - [Gubra Resource Library](https://www.gubra.dk/resource-library/) - [Bleomycin\-induced Models of BLEO\-IPF for Preclinical Studies](https://www.gubra.dk/cro-services/lung/preclinical-ipf-models/) - [Latest news](https://www.gubra.dk/news/) - [Newsletter signup](https://www.gubra.dk/newsletter-signup/) - [Career](https://www.gubra.dk/about-us/career/) - [CSR](https://www.gubra.dk/about-us/sustainability/) - [Home](https://www.gubra.dk/) ## Posts - [2026 industry trends in anti\-obesity drug development](https://www.gubra.dk/blog/2026-industry-trends-in-anti-obesity-drug-development/): Read about how anti\-obesity therapeutics in 2026 reflect a clear transition beyond first\-generation incretin\-based therapies\. - [Understanding the blood\-brain barrier: Function, structure, and role in CNS drug delivery](https://www.gubra.dk/blog/understanding-the-blood-brain-barrier-function-structure-and-role-in-cns-drug-delivery/): Explore how Gubra supports preclinical BBB studies that integrate CNS drug delivery with spatial characterization of disease biology\. - [Quantifying neurodegenerative disease with 3D Imaging: A new standard in preclinical CNS research](https://www.gubra.dk/blog/quantifying-neurodegenerative-disease-3d-imaging-preclinical-cns-research/) - [Preclinical ovary histology: AI\-assisted analysis of reproductive tissue and endpoints](https://www.gubra.dk/blog/preclinical-ovary-histology-ai-assisted-analysis-of-reproductive-tissue-and-end-points/): Explore how we perform estrous cycling to determine the estrous cycle stage of our women’s health animal models\. - [AI\-based lung histology in preclinical IPF models: Bridging preclinical and clinical insight](https://www.gubra.dk/blog/ai-based-lung-histology-in-preclinical-ipf-models-bridging-preclinical-and-clinical-insight/): Explore how AI\-driven image analysis can enhance the evaluation of complex lung pathology and support more precise, quantitative readouts in fibrosis research\. ## mfn\_news - [Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB\-003, an investigational therapy for the management of heavy menstrual bleeding](https://www.gubra.dk/mfn_news/gubra-collaboration-partner-hemab-announces-first-participant-dosed-in-phase-1-clinical-trial-of-hmb-003-an-investigational-therapy-for-the-management-of-heavy-menstrual-bleeding/) - [Gubra to present at Morgan Stanley 24th Annual Global Healthcare Conference](https://www.gubra.dk/mfn_news/gubra-to-present-at-morgan-stanley-24th-annual-global-healthcare-conference/) - [Gubra announces achievement of milestone from AbbVie following initiation of a Phase 2 clinical trial of ABBV\-295, a long\-acting amylin analog](https://www.gubra.dk/mfn_news/gubra-announces-achievement-of-milestone-from-abbvie-following-initiation-of-a-phase-2-clinical-trial-of-abbv-295-a-long-acting-amylin-analog/) - [CEO Interview\. First half\-year results 2026\.](https://www.gubra.dk/mfn_news/ceo-interview-first-half-year-2026/) - [Interim report H1 2026: Strong clinical pipeline momentum and business execution position Gubra for an exciting period ahead](https://www.gubra.dk/mfn_news/interim-report-h1-2026-strong-clinical-pipeline-momentum-and-business-execution-position-gubra-for-an-exciting-period-ahead/) ## GG in media - [Battery Storage: Building More Resilient Energy Infrastructure](https://www.gubra.dk/gg_in_media/battery-storage-building-more-resilient-energy-infrastructure/) ## IR Governance - [Article of Association](https://www.gubra.dk/ir_governance/article-of-association/) - [Corporate governance statement 2025](https://www.gubra.dk/ir_governance/corporate-governance-statement-2025/) - [Corporate governance statement 2024](https://www.gubra.dk/ir_governance/corporate-governance-statement-2024/) - [Corporate governance statement 2023](https://www.gubra.dk/ir_governance/corporate-governance-statement-2023/) - [Remuneration Policy](https://www.gubra.dk/ir_governance/remuneration-policy/) ## Resource Library items - [Adaptive oligodendrogenesis regulates blood\-hypothalamus barrier permeability, hypothalamic glucose sensing and systemic glucose homeostasis in male mice](https://www.gubra.dk/resource-library/adaptive-oligodendrogenesis-regulates-blood-hypothalamus-barrier-permeability-hypothalamic-glucose-sensing-and-systemic-glucose-homeostasis-in-male-mice/) - [Automated AI\-assisted estrous cycle staging in rodent models of reproductive disorders](https://www.gubra.dk/resource-library/automated-ai-assisted-estrous-cycle-staging-in-rodent-models-of-reproductive-disorders/) - [Differential Therapeutic Profile of Efruxifermin in the​ GAN DIO\-MASH and CDAA\-HFD Mouse Models of MASH​](https://www.gubra.dk/resource-library/differential-therapeutic-profile-of-efruxifermin-in-the-gan-dio-mash-and-cdaa-hfd-mouse-models-of-mash/) - [Nephroprotective effects of dapagliflozin in the adenine\-diet induced mouse model of chronic kidney disease](https://www.gubra.dk/resource-library/nephroprotective-effects-of-dapagliflozin-in-the-adenine-diet-induced-mouse-model-of-chronic-kidney-disease/) - [Time course of hypertensive diabetic kidney disease in uninephrectomized db/db mice](https://www.gubra.dk/resource-library/time-course-of-hypertensive-diabetic-kidney-disease-in-uninephrectomized-db-db-mice/) ## Feed Items - [Kun 1\.200 virksomheder ejer over halvdelen af markerne i Danmark](https://www.gubra.dk/wprss_feed_item/kun-1-200-virksomheder-ejer-over-halvdelen-af-markerne-i-danmark/): Blandt investorerne er Gubra\-stifter Jacob Jelsing og tidligere Novo Nordisk\-direktør Lars Fruergaard Jørgensen\. - [3 European Life Science Tools Stocks Investors May Want To Watch Now](https://www.gubra.dk/wprss_feed_item/3-european-life-science-tools-stocks-investors-may-want-to-watch-now/): SWX:TECN Revenue \& Expenses Breakdown as at Sep 2026 Gubra \(CPSE:GUBRA\) Gubra plugs directly into the European Life\-Science Tools and Clinical Research Enablers theme, running a peptide\-focused preclinical - [Linkedin: Healthcare Market Insights](https://www.gubra.dk/wprss_feed_item/linkedin-healthcare-market-insights/): Biosciences, The Jackson Laboratory, Crown Bioscience, Frontage Laboratories, Inc, Sygnature Discovery, Concept Life Sciences, genOway, JANVIER LABS, Scantox Group, Pharmidex, Transpharmation Ltd\., Gubra - [Lyn\-analyse: Danmark har brug for vækstvindere \- Gubra vokser med 892 pct\.](https://www.gubra.dk/wprss_feed_item/lyn-analyse-danmark-har-brug-for-vaekstvindere-gubra-vokser-med-892-pct/): Gæst: Matilde Krogsgaard, journalist, Finans Vært: Mads Ring Hent alle afsnit af Finans Podcasts i Apple Podcast på Spotify eller lyt til alle afsnit direkte her Gubra udvikler egne lægemidler mod - [Fra en af Danmarks dyreste ejendomme til personlig konkurs: Peter Norvig og Hanne Nørrisgaard](https://www.gubra.dk/wprss_feed_item/fra-en-af-danmarks-dyreste-ejendomme-til-personlig-konkurs-peter-norvig-og-hanne-norrisgaard/): Seks nye milliardærfamilier er kommet på Top 100\-listen, bl\.a\. familien Kristiansen/Detlefsen, Hans Christian Munck, Jeanette Rohde Christensen og Jacob Jelsing fra Gubra\. ## Governance categories - [Governance documents](https://www.gubra.dk/governance_categories/governance/) - [AGM/EGM 2024](https://www.gubra.dk/governance_categories/agm-2024/) - [AGM/EGM 2025](https://www.gubra.dk/governance_categories/agm-2025/) - [Remuneration and Nomination Committee](https://www.gubra.dk/governance_categories/remuneration-and-nomination-committee/) - [Audit Committee](https://www.gubra.dk/governance_categories/audit-committee/) ## Event types - [Other Events](https://www.gubra.dk/eventtypes/other-events/) - [Financial Calendar](https://www.gubra.dk/eventtypes/financial-calendar/) ## Optional - [Sitemap index](https://www.gubra.dk/sitemap_index.xml)